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Abstract 
 
 
 
 
 
 
 
Prognostic markers derived from standard ECG have always been seductive. 
Increased dispersion of durations of the P wave, of the QRS complex, or of the QT 
interval has been associated with the risk of atrial fibrillation, ventricular 
arrhythmias, sudden cardiac death, as well as with a general negative prognosis in 
various settings.  
However, these markers have intrinsic and methodological issues that question 
their utility. This paper presents data supporting the utility of QRS dispersion in 
clinical practice. Our investigation shows that QRS dispersion is a simple 
electrocardiographic marker with potential value in the assessment of patients in a 
variety of clinical settings: ischemic heart disease, heart failure, and 
cardiomyopathies.  
More studies are needed to validate QRS clinical utility for predicting the risk 
for ventricular arrhythmias and sudden cardiac death, and for the evaluation of the 
response to cardiac resynchronization therapy. 
 
 
Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, 
papules, pustules, nodules and sometimes hematic or meliceric crusts, located on the face, trunk, neck, arms 
and buttocks.  
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Introduction 
QRS complex refers to the combination of three of 
the graphical deflections seen on a typical 
electrocardiogram (ECG). QRS dispersion is defined as 
the difference between the maximum and minimum 
QRS duration measured in the standard twelve lead 
ECG. It has been suggested that an increased QRS 
dispersion (QRSd) is a marker of inhomogeneous 
ventricular depolarization and could be associated with 
negative prognosis (1). 
Dispersion of surface ECG wave durations or 
intervals (P wave, QRS, QT interval, JT interval) has 
been assiduously studied in the search for non-invasive 
cardiac markers useful in predicting the risk of atrial 
fibrillation, ventricular arrhythmia, and sudden cardiac 
death, and also as nonspecific prognosis markers. The 
largest body of data refers to QT dispersion (QTd), but, 
after an initial flurry of positive results, the potential 
significance of QT dispersion slowly entered into 
obscurity, due to a number of fundamental issues (2). 
The most important criticism is based on the way the 
ECG is constructed and derived from the projection of 
the electrical activity loops. It has been suggested that, at 
least in limb leads, QT-d is an ‘illusion’. Other 
methodological issues in QT dispersion are associated 
with its poor reproducibility, mostly due to the difficulty 
of identifying T wave offset. Some authors have 
extended the same arguments to P wave dispersion (3), 
but the question arises as to whether they also affect 
QRS dispersion. 
As Batchvarov stated (4) ‘‘the clinical significance 
of an ECG marker should be proved or disproved on the 
basis of its reproducibility and its link to important 
clinical events or other clinical variables (or lack 
thereof). Attempts to bolster its clinical significance by 
speculating about underlying electrophysiological 
mechanism (for example in manuscripts reporting purely 
clinical ECG studies) should be discouraged’’.  
In this paper, we review studies supporting the need 
for continued research into QRSd and argue that 
abandoning its potential utility should not occur just 
because of insufficient knowledge regarding its 
electrophysiological basis. 
 
Discussion 
Does QRS dispersion have an electrophysiological 
basis? Differences in excitation times of the normal 
human heart 
 
Durrer et al., as early as in 1970, reviewed several 
studies and considered: ‘‘knowledge of the time course 
and instantaneous distribution of the excitatory process 
of the normal human heart would be of value for 
understanding the QRS complex’’ (5).  
They studied seven re-perfused normal human hearts 
which were removed within half an hour after death. 
Electrocardiograms taken before death were not 
suggestive of heart disease. The hearts were maintained 
under physiological conditions for conducting the study, 
with cardiac electrical activity recorded using epicardial 
and intramural electrodes. The overall pattern of the left 
ventricle (LV) depolarization showed the synchronous 
excitation of 3 endocardial areas, 0-5 ms after the start of 
depolarization:  (1) an area on the upper anterior 
paraseptal wall, extending toward the apex into the 
region anterior papillary muscle insertion; (2) a central 
area on the left side of the interventricular septum; and 
(3) the posterior paraseptal area. These areas of electrical 
activation extend into the next 5-10 ms, and merge at 15-
20 ms after the onset of excitation. At this time, the 
activation front envelops a great part of the ventricular 
cavity except for a postero-basal area, a middle lateral 
area, and an apical anterior area. This movement around 
the cavity is much more rapid than the spread toward the 
epicardium. Activation of the right ventricle starts 5-10 
ms after that of LV, near anterior papillary muscle 
insertion, then spreads to the septum and free wall. 
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Epicardial breakthrough is recorded in the pre-trabecular 
area after 20 ms, reaching pulmonary conus and the 
postero-basal area at 60-70 ms. The epicardial excitation 
pattern reflects the intramural excitation wave. 
Cassidy et al. performed an endocardial mapping of 
the sinus rhythm in 15 patients without known heart 
disease (6). Their results are similar to the findings of 
Durrer et al.; furthermore they suggested that, after 
initial activation, electrical activity spreads radially and 
rapidly from these breakthrough points to converge at 
the apex and finally the infero-posterior base. The 
observation that the apex is activated ‘relatively late’ 
(last 25% of left ventricular endocardial activation) had 
not been noted previously.  Left ventricular endocardial 
activation began at 0-15 ms after the QRS complex 
onset. Endocardial activation of LV was completed at 
29-52 ms. The duration of LV endocardial activation 
was 28-50 ms. This comprised 41% of the total surface 
QRS complex (mean QRS duration 87 ms, range 80-100 
ms). 
Wyndham et al. (7) recorded the epicardial 
ventricular depolarization sequence in 11 patients with 
normal QRS who were suffering from coronary artery 
disease and underwent heart surgery. They concluded 
that their data could be useful as a basis for comparison 
with the abnormal epicardial activation sequence in 
ventricular pre-excitation and ventricular tachycardia. 
Knowledge of the range of normality in epicardial 
activation sequence could also provide a basis for 
interpretation of the disordered sequence seen in chronic 
or surgically induced intraventricular conduction defects. 
The heterogeneity and conduction delays described 
above are relevant to the basis for the QRS dispersion 
(QRSd) existence, even in the normal heart and in 
different clinical situations in which the myocardium 
depolarization is affected. Precordial leads reflect local 
electrical activity, and thus QRS dispersion is an 
approximate marker of this in homogeneous 
depolarization. 
QRS dispersion in myocardial infarction patients 
Perkiömäki and colleagues studied a set of 100 
patients: 30 healthy subjects, 40 patients with a history 
of myocardial infarction (MI), without arrhythmic events 
or inducible ventricular tachycardia (VT) at 
electrophysiological study (EPS), and 30 patients with 
prior MI and history of cardiac arrest (12 patients) or VT 
(18 subjects) and inducible monomorphic VT at 
electrophysiological study (8). Although the focus was 
QT dispersion (QTd), QRSd was also measured. QRS 
dispersion was 28 ± 11 ms in the normal group, 46 ± 13 
ms in the group with MI and no VT, and 48 ± 16 ms in 
the group with MI and VT (p < 0.001 between patients 
without VT vs. healthy subjects and between patients 
with VT vs. healthy subjects). The maximal and minimal 
QRS duration were also higher in patients with prior MI 
compared to healthy subjects (p < 0.001).  
A more extensive study which included 724 patients 
(9) showed that increased QRS duration (> 110 ms) or 
dispersion was not correlated with arrhythmic events, 
and also QRS dispersion was not correlated with death 
during follow-up. 
The effect of therapy of acute MI on QRSd was 
analyzed mostly indirectly in studies with other main 
targets. Moreno et al., in a pre-primary PCI era study, 
analyzed the effect of thrombolysis on QTd and QRSd 
(10). They included 244 patients with AMI treated with 
streptokinase or anistreplase. Dispersion of QT, JT, and 
QRS were measured at 9 ± 5 days after thrombolytic 
therapy by using a computerized method. The maximal 
QRS interval was 93 ± 11 ms and was observed in a 
precordial lead in 56% of patients and from one of the 
limb leads in 44%. The minimal QRS interval was 68 ± 
10 ms and was noticed in a precordial lead in 39% of 
patients and in limb leads in 61%. The average QRSd 
was 24 ± 9 milliseconds (range: 6 - 58 ms). QRSd was 
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not correlated with the perfusion grade observed at 
coronary angiography (25 ± 10 ms in grade TIMI 0, 22 ± 
7 ms in grade TIMI 1, 28 ± 9 ms in grade TIMI 2, and 24 
± 9 ms in grade TIMI 3; p = 0.24). 
Mozos studied 16 patients (13 men, 3 women) with 
prior MI (occurring at least one year prior), searching for 
correlations between signal-averaged late ventricular 
potentials (LVP) and 12-lead ECG dispersion indices 
(QRS, QT and JT intervals) (11). Patients with 
hypokalemia, hypocalcemia, or hypomagnesaemia and 
those not in sinus rhythm were excluded. There were 6 
patients in class III NYHA heart failure. QRS dispersion 
was measured manually using at least 8 leads for each 
patient. The following parameters regarding 
depolarization were calculated: QRS dispersion (QRSd), 
QRSdc (heart rate corrected QRSd), QRScmax (heart 
rate corrected maximum QRS duration) and QRScmin 
(heart rate corrected minimum QRS duration). The 
values were compared in two groups of patients: with 
and without LVP (62.5% had LVP+). The depolarization 
dispersion parameters had the following values: QRSd = 
120 ± 90 ms (110.4 ms in LVP+ vs. 56.8 ms in LVP-, p 
= 0.05), QRSdc = 32 ± 27 ms (23.8 ms in LVP+ vs. 
12.16 ms in LVP-, p = 0.05), QRSmax = 50 ± 30 ms 
(43.8 ms in LVP+ vs. 30.83 ms in LVP-, p = 0.048), 
QRSmin 17 ± 11 ms (18.9 ms in LVP+ vs. 18.66 ms in 
LVP-, p = ns). QRSd correlated with SAECG QRS 
duration (r = 0.61, Bravais-Pearson) and LAS40 (r = 
0.78). QRSdc correlated with SAECG QRS duration (r = 
0.48) and LAS40 (r = 0.78). QRSmax correlated with 
SAECG QRS duration (r = 0.61) and LAS40 (r = 0.72). 
Other indices had weak correlations. Given the small 
number of patients, the significance of the results to the 
larger population remains unclear. 
QRD dispersion in heart failure 
Anastasiou-Nana et al. followed 104 class II-IV 
NYHA heart failure patients with systolic dysfunction 
(left ventricular ejection fraction < 35%) for 20 ± 12 
months, with cardiac death as the end-point (12). QRS 
dispersion was measured using computer software. QRS 
dispersion was increased in non-survivors (54 ± 17 ms 
vs. 46 ± 16 ms, p < 0.02). Also, patients with sudden 
death had significantly higher QRSd compared to 
survivors (56 ± 13 ms vs. 46 ± 16 ms, p < 0.02). Using a 
cut-off value of 46 ms for QRSd identified a group with 
high risk of death in three years (mortality 13% vs. 32%, 
relative risk 3.85, 95% confidence interval 1.6 to 9.5). 
The risk was even higher by adding QTd> 90 ms. In a 
multivariate regression analysis, QRSd was an 
independent predictor of cardiac death (p = 0.001) and of 
sudden cardiac death (p = 0.04). 
Yamada et al. studied 87 patients with left 
ventricular ejection fraction (LVEF) less than 40% 
(measured by magnetic resonance imaging) (13). 
Cardiac mortality was higher in patients with both 
abnormal QRSd (> 25 ms) and QTcd (> 62 ms), with 
better positive predictive value than in those with just 
one abnormal parameter (63% vs 15%, p = 0.01). 
QRS dispersion was incorporated into a prognostic 
index assessing the long-term mortality of 553 patients 
with class I-III NYHA heart failure from the UK-
HEART study (14). Mean QRSd was 44.6 ± 15.5 ms, 
median was 42.7 ms, range 12 – 125 ms. In survivors 
QRSd was 40.6 ms compared with 45.1 ms in non-
survivors (geometric means, p = 0.003). QRSd was an 
independent predictor of all-cause mortality with a 
hazard ratio of 1.06 (1.02 – 1.1), p = 0.004. The 
following predictors of mortality were included in the 
score, with one point each: serum sodium ≥ 140 mmol/l, 
creatinine ≥ 111 mmol/l, cardiothoracic ratio ≥ 0.52, 
SDNN ≥ 112 ms, maximum QTc ≥ 487 ms, QRS 
dispersion ≥ 42.7 ms, the presence of non-sustained VT 
on 24-hours Holter recordings and LV hypertrophy in 
12-lead ECG. In the low-risk group (0–3 points) 
mortality at 5 years was 20% compared to 53% in the 
high-risk group (4–8 points). The study was developed 
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before the era of beta-blockers in heart failure started, so 
the results need to be confirmed with current standards-
of-care. Another point worth mentioning is the need to 
compare this prognostic score with other well-
established easy-to-obtain risk variables, including left 
ventricular ejection fraction, given the fact that this score 
included a time-consuming mix of blood tests, imaging, 
and electrocardiographic techniques. 
QRD dispersion in left bundle branch block 
Wyndham et al. showed that in patients with left 
bundle branch block (LBBB), the onset of ventricular 
epicardial activation is closer to anterior right ventricle 
than in normal activation, with slow trans-septal 
activation of LV (7). 
Xiao et al. studied the correlation between QRSd 
and LV function and the asynchrony of ventricular 
motion in patients with LBBB (15). Forty-two patients 
with LBBB and 28 normal controls (group C) were 
included. The LBBB patients were divided into two 
groups: the isolated LBBB patients (group A, n = 7), and 
LBBB patients with other organic diseases (group B, n = 
35). All the indices were significantly different between 
group B and group C (p < 0.05), except for LVEF. All 
the indices were significantly different between group A 
and group B, except for QRS duration. The QRS 
duration and QRSd were negatively correlated with LV 
ejection fraction in the two LBBB groups, with the 
correlation of r = -0.310 (p = 0.046) for QRS duration 
and r = -0.341 (p = 0.027) for QRSd; QRSd and LV 
systolic asynchrony index (evaluated by echo-
cardiography) were positively correlated, with the 
correlation of r = 0.318 (p = 0.040). 
Is QRS dispersion a potential predictor of response 
to cardiac resynchronization therapy?  
QRS duration and morphology are important criteria 
for the indication of cardiac resynchronization therapy 
implantation. In this setting, QRSd was investigated as a 
possible marker of therapy response. Seventy-six 
patients with CRT device implant were divided by Qiao 
and colleagues into three groups: non-responders (n = 
23), responders (n = 37) and super-responders (n = 16) 
(16). Responders met all the following criteria: no 
cardiovascular death, no heart transplantation, no 
hospitalization for decompensated heart failure, and 
improvement of NYHA class. A patient was classified as 
a super-responder if LVEF was ≥ 50% at follow-up. 
QRS duration and dispersion were measured on standard 
12-lead ECGs at a paper speed of 25 mm/s before and 
immediately after the implantation. Pre-implant QRSd 
was 49.5 ± 18.1 ms in non-responders, 43.5 ± 17.0 ms in 
responders, 38.7 ± 19.2 in super-responders (p = ns). 
Post-implant QRSd was 40.1 ± 27.9 ms in non-
responders, 32.9 ± 21.5 ms in responders, 25.0 ± 15.9 ms 
in super-responders (p < 0.05 compared with non-
responders). In a multivariate analysis, none of the 
variables was independently associated with CRT non-
response. 
However, other authors found that, unlike QRS 
maximum duration, QRSd was not a significant 
predictor of maximum hemodynamic change in patients 
that have undergone cardiac resynchronization therapy 
(17). 
Dilaveris et al. studied the effects of biventricular 
pacing on ventricular depolarization and repolarization 
(by ECG and vectorcardiography) (18). They found QRS 
duration and dispersion significantly decreased as effect 
of resynchronization therapy.  
Chávez-González et al. selected 19 patients with 
LBBB, LVEF ≤ 35% and resynchronization therapy 
(19). QRSd was higher in women (48.0 ± 24.0 ms vs. 
37.14 ± 13.8 ms; p=0.04) and decreased after 
resynchronization, especially in responders. There was a 
linear correlation between LVEF and QRSd (r=0.34, 
p=0.02 at six months follow-up). Considering this 
research, the same group proposes that besides duration, 
QRS dispersion should be measured in future 
Ionuț Donoiu et al. 
137 
 
investigations about resynchronization therapy, in order 
to reach better predicting indexes for such electrical 
therapy (20). 
QRS dispersion in cardiomyopathies 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) is an inherited disease in which there is a 
gradual replacement of ventricular myocardium with 
fibro-fatty tissue, initially predominantly in the right 
ventricle, with its main feature being the risk of 
malignant ventricular arrhythmias. The replacement of 
cardiomyocytes with adipose or fibro-fatty tissue 
determines the development of viable myocardium 
islands surrounded by inert areas, with severely altered 
electrical continuity. The isolated areas are depolarizing 
significantly later than normal ones and induce QRS 
duration prolongation in leads facing directly the 
affected area (i.e., usually V1-V3), with increased QRS 
dispersion, or if the conduction is even slower, the 
appearance of a low-amplitude signal at the end of QRS 
complex (ε - epsilon wave).  
To be visible as a separate wave on the surface ECG, 
this late depolarizing area must have a sufficient size and 
must depolarize uniformly though later than in the case 
of a block of one of the His-Purkinje network bundles. 
The diagnosis of ARVC is established with the 2010 
Task Force Criteria, and includes the following types of 
findings: global and/or regional myocardial dysfunction 
and structural abnormalities in imaging assessment, 
histopathology (endomyocardial biopsy), repolarization 
abnormalities on 12-lead ECG, depolarization 
abnormalities on 12-lead ECG, arrhythmias, family 
history and genetics (21). Depolarization abnormalities 
included are: ε wave in V1–3 (reproducible low-
amplitude signals between end of QRS complex to onset 
of the T wave, major criterion), and signal-averaged 
ECG with late potentials (if QRS on standard surface 
ECG < 110 ms, minor criterion) (21). 
QRS dispersion has been proposed as a criterion for 
the diagnosis of ARVC. Turrini and colleagues 
investigated the value of QRSd as a noninvasive marker 
of sudden death in 20 sudden death victims with ARVC 
diagnosed at autopsy (group I), 20 living ARVC patients 
with sustained VT (group II), 20 living ARVC patients 
with ≤ 3 consecutive premature ventricular beats (group 
III), and 20 control subjects (group IV) (22). QRSd was 
greater in group I compared with group II (45.7 ± 8.1 ms 
vs. 33.5 ± 8.7 ms, p = 0.0004) and in group II compared 
with group III (33.5 ± 8.7 ms vs. 28 ± 5.2 ms, p < 
0.0001) and group IV (33.5 ± 8.7 ms vs. 18.5 ± 3.6 ms, p 
< 0.0001). A QRSd ≥ 40 ms had a sensitivity of 90% and 
a specificity of 77% in identifying patients at risk of 
sudden death. QRS dispersion was the only independent 
predictor of sudden death in a multivariate analysis, 
excepting a history of syncope (odds ratio 1.22, CI 1.11 - 
1.35; p < 0.0001) (22). 
The value of QRSd as an independent predictor of 
sudden death in ARVC has been confirmed in other 
studies. Nasir and co-workers analyzed a number of 
ECG characteristics in 50 patients with ARVC, 50 
matched controls, and 28 patients with right ventricular 
outflow tract tachycardia (23). QRSd ≥ 40 ms was 
present in 44% of patients with ARVC without right 
bundle branch block (RBBB) vs. 4% in right ventricular 
outflow tract (RVOT) tachycardia group (p < 0.0001) vs. 
0% in normal controls (p < 0.0001). The presence of 
RBBB had no influence on dispersion. In patients 
without RBBB the only significant predictors of 
inducibility of VT at EPS after logistic regression 
analysis were prolonged S-wave upstroke in V1 through 
V3 ≥ 70 ms (odds ratio 7.2; 95% CI 1.2 - 43.8; p = 0.03) 
and QRS dispersion ≥ 40 ms (odds ratio 6.1; 95% CI 1.0 
- 37.6; P = 0.05). It has been reported that a QRS 
dispersion ≥ 50 ms was a predictor of recurrent 
arrhythmic events in a cohort of 121 consecutive patients 
(24). Hulot et al. confirmed the value of QRS dispersion 
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as a risk factor for cardiovascular death in a cohort of 
130 patients (100 men; age at onset of symptoms, 31.8 ± 
14.4 years) followed-up 8.1 ± 7.8 years (25). QRS 
dispersion > 40 ms was recorded in 40% of the patients 
and was significantly more frequent in the group with 
cardiovascular death compared with the group of 
survivors or with non-cardiovascular death (57.1% vs. 
36.7%, p = 0.08). QRS dispersion > 40 ms was a 
predictor of cardiovascular death (OR = 2.30, 0.89 - 
5.95, p = 0.08) comparable with recurrence of 
ventricular tachycardia. The best predictor was the 
presence of right heart failure (odds ratio = 10.99) (25). 
Electrocardiographic abnormalities in ARVC, 
including QRS dispersion, are dynamic features of 
ARVC, as was demonstrated in a study on 317 ECGs 
from 68 genotyped patients (34 with disease-causing 
mutations) during follow-up of 34 ± 28 months (26). In 
this cohort, 23% of patients had new or dynamic ECG 
changes. ECG changes present at baseline were: T wave 
inversion beyond V2 (39.7%), epsilon waves (5.9%), 
localized prolongation of the QRS complex in V1-V3 
(14.7%), and QRS dispersion ≥ 40 ms (10.3%). QRS 
dispersion was relatively stable during follow-up with no 
significant changes in 89.7% without QRSd at baseline 
and 8.8% of patients with QRSd at baseline. Very 
interestingly, in one patient QRSd was present at 
baseline but normalized during follow-up, due to QRS 
prolongation in left precordial leads, supposedly through 
left ventricular involvement. This evolution of QRSd is 
consistent with the hypothesis of a correlation between 
electrocardiographic dispersion and structural changes in 
the myocardium, but also suggests that in more 
advanced disease states with bi-ventricular involvement, 
QRSd may lose sensitivity (26). 
Cardiac magnetic resonance (CMR) imaging is an 
important tool for diagnosis of ARVC. A study by Ma 
and colleagues assessed the correlations between the 
presence of right ventricular abnormalities detected by 
CMR and QRS dispersion in 40 consecutive patients 
(27). Using the cut-off value of 40 ms for QRSd 
separated the patients in two groups with significant 
structural differences. Patients with QRSd ≥ 40 ms had 
higher dimensions of right ventricle function: end-
diastolic diameter (57 ± 10 mm vs. 48 ± 11 mm, p = 
0.012), end-systolic diameter (52 ± 10 mm vs. 44 ± 11 
mm, p = 0.010), end-diastolic volume (260 ± 105 ml vs. 
180 ± 66 ml, p = 0.006), end-systolic volume (222 ± 98 
ml vs. 148 ± 61 ml, p = 0.006) and higher myocardial 
fibrosis detection rate (74% vs. 38%, p = 0.024). 
Analyzing the group as a whole, QRS dispersion 
correlated significantly with right ventricular end-
diastolic volume (r = 0.66, p < 0.001), right ventricular 
end-systolic volume (r = 0.67, p < 0.001), right 
ventricular outflow tract area (r = 0.68, p < 0.001) (27). 
Hypertrophic cardiomyopathy is another 
arrhythmogenic disease in which simple, specific and 
sensitive ECG risk markers are needed. QRS dispersion 
was tested, but only indirectly and in a small number of 
patients. Sakata et al., in a retrospective analysis of 
echocardiography and electrocardiography in 70 patients 
with hypertrophic cardiomyopathy, did not find a 
correlation between QRS duration or dispersion and the 
distribution of LV hypertrophy (28). The relationship 
with wall thickness was not tested. Kawasaki et al. 
enrolled 70 patients with hypertrophic cardiomyopathy 
and anteroseptal wall hypertrophy, 8 patients with lateral 
wall hypertrophy, 8 patients with diffuse hypertrophy, 
and 46 normal controls (29). Standard 12-lead ECG 
parameters were analyzed. QRS dispersion was highest 
in the group with anteroseptal hypertrophy (43.0 ± 10.6 
ms), followed by the group with lateral wall hypertrophy 
(32.9 ± 11.9 ms). In these patients, there was a 
superposition of localization of QRS increased duration 
with the echocardiographic disposition of hypertrophy. 
The group with diffuse hypertrophy was not different 
from controls. QRS dispersion was not significantly 
Ionuț Donoiu et al. 
139 
 
different in patients with or without markers of risk 
(syncope, ventricular tachycardia, cardiac events), or 
between patients of different NYHA functional class 
(29). 
 
Conclusions 
As a conclusion, the QRS dispersion is a simple 
electrocardiographic marker with potential value in the 
assessment of patients in different clinical settings: 
ischemic heart disease, heart failure, and 
cardiomyopathies. More studies are needed to validate 
its clinical utility for predicting the risk for ventricular 
arrhythmias and sudden cardiac death, and for the 
evaluation of the response to cardiac resynchronization 
therapy. 
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